New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of preclinical biotechs filed prospectuses late Friday for NASDAQ offerings.

The group includes gene therapy company Generation Bio Co., antibody-oligonucleotide conjugate developer Avidity Biosciences Inc. and vaccine company Vaxcyte Inc., which was known as SutroVax Inc. until a few days ago. Also filing for listings were Royalty Pharma plc, which invests in biopharma royalty streams, and China's Burning Rock Biotech Ltd...